12 months	69.6%
24 months	4.3%
No	26.1%

2. Do you believe that the issue of clinical cardiac safety has been addressed by recent regulatory guidance:

Well	0%
Adequately but some issues remain	47.8%
Some major issues have not been addressed yet	43.5%
Cardiac safety issues remain largely unresolved	4.3%
Not my area of expertise	4.3%

3. In your opinion what issues are the highest priority to be addressed in clinical cardiac safety evaluation:

More accurate arrhythmia liability characterization (e.g., reduction of false-positives and false-negatives, quantitative characterization of risk when some arrhythmia risk is expected)	60.9%
Size and cost of the clinical trials	26.1%
Speed of clinical trials	0.0%
Not my area of expertise	13%
Other (please specify)

4. Are you satisfied with the current cardiac safety assessment in the clinical development phases (e.g., E14 guidance implementation)?

Very satisfied, cardiac safety assessment is no longer a problem	0.0%
Largely satisfied, but some issues remain to be addressed	34.8%
Somewhat dissatisfied, significant issues remain	56.5%
Highly dissatisfied, the issue remains largely unresolved and/or the solution introduced more problems	8.7%
Not my area of expertise	0.0%

5. Do you agree with the statement: the need to conduct a TQT study in later clinical development leads to termination of potentially useful and viable drug candidates in earlier phases (preclinical and early human trials)?

Agree	60.9%
Disagre	30.4%
Not my area of expertise	8.7%

This poll is still open.  Participate in this poll.